Pembolizumab

Phase 3Monoclonal antibody

Pembolizumab is one of 42 small molecule programs targeting Head and Neck Squamous Cell Carcinoma (HNSCC). It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Head and Neck Squamous Cell Carcinoma (HNSCC)Not yet recruiting

Gastric CancerNot yet recruiting

Head and Neck Squamous Cell Carcinoma (HNSCC)Preclinical

Not yet recruiting

Gastric CancerPhase 3

Not yet recruiting

Competition

Competitive Landscape

193 competitors in Gastric Cancer

#DrugCompanyPhaseTrials

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

55 2

Taxotere

AAvyxa

Phase 3

45 3

Cyramza

Eli Lilly

Phase 3

10 4

Beyfortus

BeiGene

Phase 3

10 5

Tuoyi

SSun Yat-sen University

Phase 3

18 6

Yervoy

Bristol-Myers Squibb

Phase 3

5 7

S-1

Taiho Oncology, Inc.

Phase 3

45 8

Apatinib

LLaNova Medicines Zhejiang Co., Ltd.

Phase 3

35 9

Mfolfox6

Roche

Phase 3

4 10

Apatinib Mesylate

BBukwang Pharmaceutical

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

PreclinicalNot yet recruiting

Head and Neck Squamous Cell Carcinoma (HNSCC)

NCT07662720

Q4 2029

Phase 2Not yet recruiting

Gastric Cancer

NCT06998771

Q4 2032

Phase 2Recruiting

Head and Neck Squamous Cell Carcinoma

NCT07485296

Phase 2/3Not yet recruiting

Gastric Cancer

NCT07332533

Clinical

Trials by Indication[1]

Gastric Cancer2 trials

JSKN003 Combined Treatment of HER2-positive Gastric Cancer

Not yet recruiting·SShanghai JMT-Bio Inc.·Phase 2·NCT06998771·153 enrolled

A Study of KN026-based Combination Therapy in HER2-positive Gastric Cancer

Not yet recruiting·SShanghai JMT-Bio Inc.·Phase 2/3·NCT07332533·490 enrolled

Head and Neck Squamous Cell Carcinoma1 trial

Effect of Postbiotics on Microbiota and Systemic Immunomodulation of Pembrolizumab as First-Line Therapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (RM HNSCC)

Recruiting·GGruppo Oncologico del Nord-Ovest·Phase 2·NCT07485296·45 enrolled

Head and Neck Squamous Cell Carcinoma (HNSCC)1 trial

A Phase I/II, Open-Label, Study to Assess the Safety, Tolerability, and Efficacy of Axelopran Administered With Standard of Care Pembrolizumab in Recurrent/Metastatic HNSCC Patients Taking Opioids to Control Cancer Pain

Not yet recruiting·GGlycyx Therapeutics·Preclinical·NCT07662720·18 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Pembolizumab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Pembolizumab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Pembolizumab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shanghai JMT-Bio Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 3[1]
Company: SShanghai JMT-Bio Inc.

Pembolizumab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Q4 2029

Q4 2032

Trials by Indication[1]

Gastric Cancer2 trials

Head and Neck Squamous Cell Carcinoma1 trial

Head and Neck Squamous Cell Carcinoma (HNSCC)1 trial

References

Drug Info

Quick Facts

Related News